The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
Open accessAbstract
Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V ± L180M. Here, we summarize results from comprehensive resistance monitoring of patients with HBV who were continuously treated with ETV for up to 5 years. Monitoring included genotypic analysis of isolates from all patients at baseline and when HBV DNA was detectable by polymerase chain reaction (≥300 copies/mL) from Years 1 through 5. In addition, genotyping was performed on isolates from patients experiencing virologic breakthrough (≥1 log 10 rise in HBV DNA). In vitro phenotypic ETV susceptibility was determined for virologic breakthrough isolates, and for HBV containing novel substitutions emerging during treatment. The results over 5 years of therapy showed that in nucleoside-naïve patients, the cumulative probability of genotypic ETVr and genotypic ETVr associated with virologic breakthrough was 1.2% and 0.8%, respectively. In contrast, a reduced barrier to resistance was observed in LVD-refractory patients, as the LVD resistance substitutions, a partial requirement for ETVr, preexist, resulting in a 5-year cumulative probability of genotypic ETVr and genotypic ETVr associated with breakthrough of 51% and 43%, respectively. Importantly, only four patients who achieved <300 copies/mL HBV DNA subsequently developed ETVr. Conclusion: Long-term monitoring showed low rates of resistance in nucleoside-naïve patients during 5 years of ETV therapy, corresponding with potent viral suppression and a high genetic barrier to resistance. These findings support ETV as a primary therapy that enables prolonged treatment with potent viral suppression and minimal resistance. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Self-citationEntecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Self-citationHepatitis B Virus Infection: Epidemiology and Vaccination
Shepard, C. W. (2006) · Epidemiologic Reviews · doi:10.1093/epirev/mxj009 · Cited by 1,148
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y., Cianciara, J., Boron–Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.007 · Cited by 413
Self-citationDas, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G., & Arnold, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4771-4779.2001 · Cited by 274
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
Yim, H. J., Hussain, M., Liu, Y., Wong, S. N., Fung, S. K., & Lok, A. S. F. (2006) · Hepatology · doi:10.1002/hep.21290 · Cited by 253
Chang, T., Gish, R. G., Hadziyannis, S. J., Cianciara, J., Rizzetto, M., Schiff, E. R., Pastore, G., Bacon, B. R., Poynard, T., Joshi, S., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.055 · Cited by 246
Self-citation
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Chronic Hepatitis B Infection: A Review
Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S. (2018) · JAMA · doi:10.1001/jama.2018.3795 · Cited by 657
Chang, T.-T., Lai, C.-L., Yoon, S. K., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., et al. (2010) · Hepatology · doi:10.1002/hep.23327 · Cited by 588
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Brown, R. S., McMahon, B. J., Lok, A. S. F., Wong, J. B., Ahmed, A. T., Mouchli, M. A., Wang, Z., Prokop, L. J., Murad, M. H., & Mohammed, K. (2016) · Hepatology · doi:10.1002/hep.28302 · Cited by 324
Liaw, Y.-F., Sheen, I.-S., Lee, C.-M., Akarca, U. S., Papatheodoridis, G. V., Wong, F. S.-H., Chang, T.-T., Horban, A., Wang, C., Kwan, P., et al. (2011) · Hepatology · doi:10.1002/hep.23952 · Cited by 316
Buti, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., Aguilar Schall, R., Flaherty, J. F., Martins, E. B., Charuworn, P., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3486-7 · Cited by 297
Shim, J. H., Lee, H. C., Kim, K. M., Lim, Y.-S., Chung, Y.-H., Lee, Y. S., & Suh, D. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.007 · Cited by 280
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., Sun, J., Li, L., Li, J., Meng, Q., et al. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00019 · Cited by 270
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Strasfeld, L., & Chou, S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.001 · Cited by 254
Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0808-5 · Cited by 185
Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.-W., Gurel, S., Caruntu, F. A., Flaherty, J. F., Massetto, B., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.028 · Cited by 147
Metadata
- Authors
- Tenney, D. J., Rose, R. E., Baldick, C. J., Pokornowski, K. A., Eggers, B. J., Fang, J., Wichroski, M. J., Xu, D., Yang, J., Wilber, R. B., & Colonno, R. J.
- Venue
- Hepatology
- Published
- 2009-05
- Volume
- 49
- Issue
- 5
- Pages
- 1503-1514
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1976104517
- Cited by
- 804
- References
- 17
- FWCI
- 51.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.